akampion News

Please click here to subscribe to regular news updates from the akampioneer.com
Wednesday, February 3, 2016

Company News: Curetis Expands Commercial Team

- Company hires Willem Haagmans as Head of Sales EMEA -

Curetis N.V. (the “Company” and, together with Curetis AG, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the expansion of its commercial and general administrative team.

As of February 1, 2016, Willem Haagmans has joined the company as Head of Sales for the EMEA region.

Willem Haagmans previously worked at Beckman Coulter as General Manager Benelux. He is a highly experienced commercial executive with a strong track record, including the successful commercialization of innovative products and solutions in the molecular diagnostics industry as well as the significant increase of top-line revenue growth. Among others, Willem Haagmans has held prior international molecular diagnostics sales management positions with Roche, Nimblegen, and Vela Diagnostics, bringing extensive leadership experience with both large and small-to-medium sized molecular diagnostics companies. He will be based in the Venlo area near the Dutch-German border, right at the heart of Curetis’ European direct sales territories, and will head all direct sales efforts in DACH, Benelux, France, UK and possibly Nordic countries.

Tuesday, February 2, 2016

Company News: Aleva Neurotherapeutics and Greatbatch, Inc. Collaborate on Next-Generation Device for Deep Brain Stimulation (DBS)

- Agreement includes strategic investment in Aleva’s current Series C round by Greatbatch, Inc. -

Lausanne, Switzerland, February 01, 2016Aleva Neurotherapeutics, a leading company developing next-generation implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and essential tremor, today announced a strategic development, supply, and manufacturing relationship with Greatbatch, Inc. (NYSE:GB). In addition, Greatbatch will invest in Aleva Neurotherapeutics’ current Series C financing round.